Bioscience (Tianjin) Diagnostic Technology Co., Ltd. is a high-tech enterprise specializing in the research, development, and manufacture of in-vitro diagnostic (IVD) instruments and reagents. Based in the Tianjin Dongli Economic Development Area, China, the company operates as a manufacturer and distributor with a workforce of 501 to 1,000 employees. Since its founding, the company has established a strong R&D presence, holding over 130 patents and maintaining collaborations with leading academic universities to advance medical science and technology.
The company's core product portfolio focuses on advanced immunoassay systems, including Chemiluminescence Immunoassay (CLIA) and Fluorescence Immunoassay (FIA) analyzers. Key offerings include the Axceed 260 automatic immunoassay analyzer and various Point-of-Care Testing (POCT) devices designed for rapid clinical diagnostics. These instruments are supported by a comprehensive range of diagnostic test kits covering tumor markers, cardiac markers, infectious diseases (including COVID-19 and Monkeypox), thyroid function, endocrine disorders, and fertility screening.
Bioscience (Tianjin) operates a factory equipped with hundred-thousand-degree purification production departments and maintains ISO 13485 certification, ensuring international quality standards for medical device manufacturing. As an active participant in global trade, the company provides OEM services and exports its diagnostic solutions to over 25 countries, including major markets in India, the Philippines, and Ukraine. Their business model integrates full-lifecycle support, from independent intellectual property development to technical marketing and after-sales assistance.
MD Pacific (Tianjin) Biotechnology Co., Ltd. is a prominent high-tech enterprise and manufacturer specializing in in vitro diagnostic (IVD) products, medical diagnostic instruments, and biotherapy ancillary products. Established in 2003 and based in the Binhai New Area of Tianjin, China, the company operates as a joint venture with Chinese, American, and German interests. With a workforce of 101 to 200 employees, the firm maintains a strong focus on research and development, supported by a postdoctoral scientific research station and 38 patents.